natgillin/translations-raw huggingface dataset:
The composition of any one of claims 1 to 16, for use in protecting dopaminergic neurons of the nigrostriatal system from degeneration. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je namijenjen upotrebi u zaštiti dopaminrgičkih neurona nigrostriatalnog sustava od degeneracije.
the dsRNA is to be administered during a prodrome, wherein preferably the prodrome is characterized by pain, nausea, psychosocial symptoms, restlessness or insomnia; or 
dsRNA se treba primijeniti tijekom prodroma, pri čemu je poželjno prodrom naznačen time da je bol, mučnina, psihološki simptomi, nemir ili nesanica; ili
D comprises a cytotoxic agent; and n is an integer from 1 to 20. 
D obuhvaća citotoksično sredstvo; i n je cijeli broj od 1 do 20.
The antibody drug conjugate for use according to any one of claims 1-20, wherein the anti-DLL3 antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, diabody, Fab fragment, F(ab')2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je protutijelo anti-DLL3 odabrano iz skupine koju čine monoklonalno protutijelo, kimerno protutijelo, CDR-cijepljeno protutijelo, humanizirano protutijelo, ljudsko protutijelo, primatizirano protutijelo, multispecifično protutijelo, bispecifično protutijelo, monovalentno protutijelo, multivalentno protutijelo, diabody, Fab-fragment, F(ab')2-fragment, Fv-fragment i ScFv-fragment; ili njegov imunoreaktivni fragment koji se specifično veže na epitop unutar DSL-domene od DLL3-proteina prema SEQ ID NO:3 ili SEQ ID NO:4.
The antibody drug conjugate for use according to any one of claims 1-22, wherein the anti-DLL3 antibody comprises or competes for binding to a human DLL3 protein with an antibody comprising a light chain variable region set forth as SEQ ID NO: 84 and a heavy chain variable region set forth as SEQ ID NO: 85. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 uključuje vezanje na ljudski DLL3-protein ili se natječe za to s protutijelom koje obuhvaća varijabilno područje slabog lanca prema SEQ ID NO:84 i varijabilno područje jakog lanca prema SEQ ID NO:85.
The antibody drug conjugate for use according to any one of claims 1-22, wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 i varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
The antibody drug conjugate of any one of claims 1-3, wherein the anti-DLL3 antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, diabody, Fab fragment, F(ab')2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof that specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je protutijelo anti-DLL3 odabrano iz skupine koju čine monoklonalno protutijelo, kimerno protutijelo, CDR-cijepljeno protutijelo, humanizirano protutijelo, ljudsko protutijelo, primatizirano protutijelo, multispecifično protutijelo, bispecifično protutijelo, monovalentno protutijelo, multivalentno protutijelo, diabody, Fab-fragment, F(ab')2-fragment, Fv-fragment i ScFv-fragment; ili njegov imunoreaktivni fragment koji se specifično veže na epitop unutar DSL-domene od DLL3-proteina prema SEQ ID NO:3 ili SEQ ID NO:4.
is a linker connected to the anti-DLL3 antibody; 
je poveznica spojena na protutijelo anti-DLL3;
An antibody drug conjugate according to any one of claims 1-22 for use in a method of treating a proliferative disorder in a subject, such as wherein the proliferative disorder is cancer, optionally wherein the cancer comprises a neuroendocrine tumor, and optionally wherein the cancer is small cell lung cancer, prostate cancer, thyroid cancer or large cell neuroendocrine carcinoma. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 22, naznačen time, da se upotrebljava u postupku liječenja proliferativnog poremećaja kod pojedinca, gdje je taj proliferativni poremećaj rak, opcijski, gdje rak obuhvaća neuroendokrinološki tumor, te opcijski, pri čemu se kod raka radi o raku malih stanica pluća, raku prostate, tiroidnom raku ili neuroendokrinološkom karcinomu velikih stanica.
A composition according to claim 1, wherein the tris-ester of phosphoric acid is tris-(2-ethylhexyl) phosphate. 
Pripravak prema zahtjevu 1, naznačen time da tris-ester fosforne kiseline je tris-(2-etilheksil) fosfat.
A composition according to claim 1 or claim 2 which is characterized by a breakdown of less than 2.5% pinoxaden after 2 weeks storage at a temperature of 50°C. 
Pripravak prema zahtjevu 1 ili zahtjevu 2 koji je naznačen time da ima raspadanje od manje od 2.5% pinoksadena nakon 2 tjedna skladištenja na temperaturi od 50°C.
80% oil carrier (different from the adjuvant or solvent carrier). 
80% uljni nosač (različit od adjuvanta ili nosača otapala).
A composition according to claim 4 wherein the solvent is a heavy aromatic hydrocarbon blend; or an alcohol or a derivative thereof selected from the group consisting of 2-ethylhexanol, n-octanol, tetrahydrofurfuryl alcohol, 2-methyl-2,4-pentanediol, 4-hydroxy-4-methyl-2-pentanone, lactic acid methylester, lactic acid butylester, cyclohexanol, benzyl alcohol, benzyl benzoate and benzyl lactate; or a mixture of one or more of these materials. 
Pripravak prema zahtjevu 4 naznačen time da otapalo je smjesa teških aromatskih ugljikovodika; ili alkohol ili njegov derivat odabran iz skupine koju čine 2-etilheksanol, n-oktanol, tetrahidrofurfuril alkohol, 2-metil-2,4-pentandiol, 4-hidroksi-4-metil-2-pentanon, metil ester mliječne kiseline, butil ester mliječne kiseline, cikloheksanol, benzil alkohol, benzil benzoate i benzil laktat; ili smjesa jednog ili više od ovih materijala.
A composition according to claim 6, wherein the solvent is tetrahydrofurfuryl alcohol, benzyl alcohol or 2-methyl-2,4-pentanediol. 
Pripravak prema zahtjevu 6, naznačen time da otapalo je tetrahidrofurfuril alkohol, benzil alkohol ili 2-metil-2,4-pentandiol.
A composition according to claim 9, wherein the safener is selected from the group consisting of cloquintocet-mexyl, mefenpyr-diethyl, and isoxadifen-ethyl. 
Pripravak prema zahtjevu 9, naznačen time da je zaštitno sredstvo odabrano iz skupine koja sadrži klokvintocet-meksil, mefenpir-dietil, i izoksadifen-etil.
A composition according to claim 1 which is in the form of an emulsion concentrate (EC), oil dispersion (OD), suspo-emulsion (SE) or emulsion in water (EW). 
Pripravak prema zahtjevu 1 naznačen time da je u obliku emulzijskog koncentrata (EC), uljne disperzije (OD), suspo-emulzije (SE) ili emulzije u vodi (EW).
A method for inhibiting or controlling undesirable plant growth, wherein a herbicidally effective amount of the composition according to claim 1 is applied to the plants or their habitat. 
Postupak za inhibiciju ili kontrolu neželjenog rasta biljaka, naznačen time da se herbicidno učinkovita količina pripravka prema zahtjevu 1 primjenjuje na biljke ili na njihov habitat.
R1, R2, R3, R4 independently of each other, represent hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted phenyl, amino, sulfonic, carboxyl, hydroxyl, nitro or halogen groups. 
, R2, R3, R4 neovisno jedan od drugoga, predstavljaju vodik, nesupstituirani C1-C4 alkil, nesupstituirani C1-C4 alkoksi, nesupstituirani aril, nesupstituirani fenil, amino, sulfonsku, karboksilnu, hidroksilnu, nitro ili halogen skupinu, gdje su R2 i / ili R3 sulfonske skupine.
A process for dyeing or printing materials, wherein the material is brought into contact with a compound of formula (1) according to any of claims 1 to 8 or prepared according to claim 9. A product or paper obtainable by a process according to claim 14. 
Postupak za bojenje ili tiskanje materijala koji sadrži celulozni i / ili lignocelulozni materijal, naznačen time, da materijal dolazi u doticaj sa spojem formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 8 ili se priprema u skladu s patentnim zahtjevom 9, pri čemu je korišteni materijal papir ili karton.
The compound according to any one of claims 1 to 12 represented by the general formula (I-2) or a pharmacologically acceptable salt thereof: wherein R7 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R8 represents a hydrogen atom or a prodrug group as defined in Claim 1. 
Spoj u skladu sa bilo kojim od patentnih zahtjeva 1 do 12 predstavljen općom formulom (I-2) ili njegova farmakološki prihvatljiva sol: [image] gdje R7 predstavlja atom vodika, C1 do C6 alkil grupu, ili C1 do C6 alkoksi grupu, i R8 predstavlja atom vodika ili grupu prolijeka kao što je definirano u Patentnom zahtjevu 1.
The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is selected from the group consisting of 
Spoj u skladu sa patentnim zahtjevom 1 ili njegova farmakološki prihvatljiva sol, gdje je spoj odabrano iz grupe koja se sastoji od
The compound according to claim 1, wherein the compound is 5-amino-2-{[1-(4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid or a pharmacologically acceptable salt thereof. 
Spoj u skladu sa patentnim zahtjevom 1, gdje je spoj 5-amino-2-{[1-(4-metilcikloheksil)-1H-imidazol-4-il]metil}valerična kiselina ili njena farmakološki prihvatljiva sol.
The compound according to claim 1, wherein the compound is 5-amino-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid or a pharmacologically acceptable salt thereof. 
Spoj u skladu sa patentnim zahtjevom 1, gdje je spoj 5-amino-2-{[1-(trans-4-metilcikloheksil)-1H-imidazol-4-il]metil}valerična kiselina ili njegova farmakološki prihvatljiva sol.
The compound according to claim 1, wherein the compound is (2S)-5-amino-2-{[1-(trans-4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid or a pharmacologically acceptable salt thereof. 
Spoj u skladu sa patentnim zahtjevom 1, gdje je spoj (2S)-5-amino-2-{[1-(trans-4-metilcikloheksil)-1H-imidazol-4-il]metil}valerična kiselina ili njegova farmakološki prihvatljiva sol.
A compound according to any one of claims 1 to 50 for use in the treatment of myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, peripheral arterial occlusion, sepsis, disseminated intravascular coagulation syndrome, or pulmonary fibrosis. 
Spoj u skladu sa bilo kojim od patentnih zahtjeva 1 do 50 za primjenu u liječenju infarkta miokarda, angine pektoris, akutnog koronarnog sindroma, cerebralnog infarkta, duboke venske tromboze, plućne embolije, periferne arterijske okluzije, sepse, sindroma diseminirane intravaskularne koagulacije, ili plućne fibroze.
Use of a compound according to any one of claims 1 to 50 or a pharmacologically acceptable salt thereof in the manufacture of a medicament for the treatment of myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, peripheral arterial occlusion, sepsis, disseminated intravascular coagulation syndrome, or pulmonary fibrosis. 
Primjena spoja u skladu sa bilo kojim od patentnih zahtjeva 1 do 50 ili njegova farmakološki prihvatljiva sol u proizvodnji medikamenta za liječenje infarkta miokarda, angine pektoris, akutnog koronarnog sindroma, cerebralnog infarkta, duboke venske tromboze, plućne embolije, periferne arterijske okluzije, sepse, sindroma diseminirane intravaskularne koagulacije, ili plućne fibroze.
Use of a pharmaceutical composition for injection containing a compound according to any one of claims 1 to 50 or a pharmacologically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the treatment of myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, peripheral arterial occlusion, sepsis, disseminated intravascular coagulation syndrome, or pulmonary fibrosis. 
Primjena farmaceutske kompozicije za injekciju koja sadrži spoj u skladu sa bilo kojim od patentnih zahtjeva 1 do 50 ili njegovu farmakološki prihvatljivu sol kao aktivni sastojak u proizvodnji medikamenta za liječenje infarkta miokarda, angine pektoris, akutnog koronarnog sindroma, cerebralnog infarkta, duboke venske tromboze, plućne embolije, periferne arterijske okluzije, sepse, sindroma diseminirane intravaskularne koagulacije, ili plućne fibroze.
The apparatus (1) according to one or more of the preceding claims, which further comprises a fluid medium-powered engine (49) that is associated via connection with said at least one evacuation outlet (34) for the treatment of the combustion gases and for the rotary actuation of a driving shaft (50). 
Uređaj (1) u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačen time, da nadalje sadržava motor pogonjen fluidnim medijem (49), koji je povezan priključkom na navedeni najmanje jedan izlazni otvor za evakuaciju (34) za obradu plinova za izgaranje i za rotacijsko pokretanje pogonske osovine (50).
A is selected from 
A je odabran od sljedećih:
is selected from H, methyl, chloro and fluoro; 
je odabran od sljedećih: H, metil, kloro i fluoro;
with the proviso that when ring C is i: 
pod uvjetom da, kada prsten C predstavlja i:
A is: is selected from methyl, chloro and fluoro, 
je odabran od sljedećih: metil, kloro i fluoro, B je:
a protein comprising the amino acid sequence of SEQ ID N°2; 
protein koji ima aminokiselinski slijed SEQ ID NO:2;
a DNA comprising the nucleotide sequence of SEQ ID N°1; 
DNA koja ima nukleotidni slijed SEQ ID NO:1;
a DNA that hybridizes with a DNA comprising the nucleotide sequence complementary to SEQ ID N°1 and encodes a protein having a fructosyl-transferase activity; and 
DNA koja hibridizira s DNA koja ima nukleotidni slijed komplementaran onom u SEQ ID NO:1 i kodira protein s aktivnošću fruktozil-transferaze; i
a DNA comprising a nucleotide sequence having a homology of at least 50% with the nucleotide of SEQ ID N°1 and encoding a protein having a fructosyl-transferase activity. 
DNA koja ima nukleotidni slijed homologan najmanje 50% nukleotidu u SEQ ID NO:1 i kodira protein s aktivnošću fruktozil-transferaze.
A recombinant microorganism according to claim 6 which is derived from Escherichia coli 05:K4:H4U1-41 strain. 
Rekombinantni mikroorganizam u skladu s patentnim zahtjevom 6, naznačen time što je izveden iz soja Escherichia coli 05:K4:H4U1-41.
A recombinant microorganism according to claim 8 which is Escherichia coli DSM23644. 
Rekombinantni mikroorganizam u skladu s patentnim zahtjevom 8, naznačen time što je Escherichia coli DSM23644.
A method for biotechnological production of chondroitin, comprising the following steps: 
Postupak biotehnološke proizvodnje hondroitina, naznačen time što se sastoji u sljedećim koracima:
Extruded, formulated fish feed containing less than 10 percent by weight of ash, more than 20 percent by weight of fat, less than 20 percent by weight of a starch-containing raw material, and astaxanthin, characterised in that the fish feed contains at least one water-soluble antioxidant selected from a group consisting of gallic acid and syringic acid, wherein the water-soluble antioxidant is present in an amount from 10 to 75 ppm or an amount from 76 to 750 ppm based on the total weight of the feed, and wherein the fish feed contains from 10 to 40 mg of astaxanthin per kg feed. 
Ekstrudirana, formulirana hrana za ribe koja sadrži manje od 10 masenih postotaka pepela, više od 20 masenih postotaka masti, manje od 20 masenih postotaka sirovine koja sadrži škrob, te astaksantin, naznačena time da hrana za ribe sadrži barem jedan antioksidans koji je topiv u vodi odabran iz skupine koju čine galna kiselina i siringinska kiselina, pri čemu je antioksidans koji je topiv u vodi prisutan u količini od 10 do 75 ppm ili u količini od 76 do 750 ppm u odnosu na ukupnu masu hrane, te pri čemu hrana za ribe sadrži od 10 do 40 mg astaksantina po kg hrane.
, R2, R3, R4 independently of each other, represent hydrogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy, unsubstituted aryl, unsubstituted phenyl, amino, sulfonic, carboxyl, hydroxyl, nitro or halogen groups, wherein R2 and/or R3 are sulfonic groups. 
, R2, R3, R4 neovisno jedan od drugoga, predstavljaju vodik, nesupstituirani C1-C4 alkil, nesupstituirani C1-C4 alkoksi, nesupstituirani aril, nesupstituirani fenil, amino, sulfonsku, karboksilnu, hidroksilnu, nitro ili halogen skupinu, gdje su R2 i / ili R3 sulfonske skupine.
Use of a compound of formula (1) according to any of claims 1 to 8, for dyeing or printing materials containing cellulose and/or lignocellulosic material, wherein the material used is paper or board. 
Upotreba spoja formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 8, za bojenje ili tiskanje materijala koji sadrže celulozni i / ili lignocelulozni materijal, pri čemu je materijal koji se koristi papir ili karton.
A process for dyeing or printing materials containing cellulose and/or lignocellulosic material, wherein the material is brought into contact with a compound of formula (1) according to any of claims 1 to 8 or prepared according to claim 9, and wherein the material used is paper or board. 
Postupak za bojenje ili tiskanje materijala koji sadrži celulozni i / ili lignocelulozni materijal, naznačen time, da materijal dolazi u doticaj sa spojem formule (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 8 ili se priprema u skladu s patentnim zahtjevom 9, pri čemu je korišteni materijal papir ili karton.
A pyrazoline dione derivative according to any one of claims 1 to 9 for use in the treatment of a disease or condition selected from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, diseases or disorders of the gastrointestinal system, angiogenesis, angiogenesis-dependent conditions and other diseases and/or disorders associated with Nicotinamide adenine dinucleotide phosphate (NADPH) Oxidase. 
Derivat pirazolin diona prema bilo kojem od zahtjeva od 1 do 9, za upotrebu u liječenju bolesti ili stanja izabranog od kardiovaskularnih poremećaja, respiratornih poremećaja, poremećaja metabolizma, kožnih poremećaja, koštanih poremećaja, neuroinflamatornih i/ili neurodegenerativnih poremećaja, bolesti bubrega, poremećaja reprodukcije, bolesti koje pogađaju oko i/ili očnu leću i/ili stanja koja pogađaju unutarnje uho, upalni poremećaji, bolesti jetra, bol, tumori, alergijski poremećaji, traume, sepse, hemoragični i anafilaktički šok, bolesti ili poremećaji gastrointestinalnog sustava, angiogeneze, stanja koja zavise od angiogeneze i drugih bolesti i/ili poremećaji koji su povezani s nikotinamid adenin dinukleotid fosfat (NADPH) oksidazom.
about 0.1 to 20 weight % of a disintegrant; 
otprilike 0,1 do 20%, težinski, sredstva za raspadanje;
about 0.1 to 10 weight % of a glidant; 
otprilike 0,1 do 10%, težinski, sredstva za kliženje;
about 0.1 to about 30 weight % sodium bicarbonate. 
otprilike 0,1 do otprilike 30%, težinski, natrijevog bikarbonata.
The solid dispersion for use of Claim 20, wherein the cancer is selected from breast, gastric, biliary, colorectal, lung, non-small cell lung cancer, pancreatic, head and neck, ovarian, uterine and brain cancer. 
Čvrsta disperzija, namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se rak bira između raka dojke, želuca, žučovoda, kolorektalnog raka, pluća, velikih stanica pluća, gušterače, glave i vrata, jajnika, maternice i raka na mozgu.
A method of determining the presence or absence of an antibody that specifically binds to a bovine viral diarrhea virus (BVDV) Erns protein in a competitive ELISA, assay, said method comprising the steps of: 
Postupak određivanja prisutnosti ili odsutnosti protutijela koje se specifično veže na protein Erns virusa goveđe virusne dijareje (BVDV) u kompetitivnom ELISA ispitivanju, naznačen time što se navedeni postupak obuhvaća korake:
incubating a cattle serum sample in the presence of pronghorn pestivirus Erns protein to which antibodies that cross-react with wild-type BVDV Erns protein are able to bind, wherein said sample is incubated either prior to or simultaneously with step b); 
inkubiranje uzorka goveđeg seruma u prisutnosti proteina Erns virusa kuge vitoroge antilope na koji se mogu vezati protutijela koja unakrsno reagiraju s proteinom Erns iz divljeg tipa BVDV, gdje se navedeni uzorak inkubira bilo prije ili istodobno s korakom b);
adding said incubated sample to an assay plate coated with the BVDV Erns protein to which said antibody to be detected binds specifically; and 
dodavanje navedenog inkubiranog uzorka na ploču za ispitivanje, obloženu BVDV proteinom Erns, na koji se specifično veže navedeno protutijelo koje treba detektirati; i
subsequently detecting in said sample the presence or absence of said antibody. 
naknadno detektiranja prisutnosti ili odsutnosti navedenog protutijela u navedenom uzorku.
The method of claim 1 or 2, wherein the presence of said antibody indicates that the animal has either been infected with wild-type BVDV or immunized with a conventional BVDV vaccine. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što prisutnost navedenog protutijela ukazuje da je životinja bilo zaražena divljim tipom BVDV ili je imunizirana uobičajenim cjepivom protiv BVDV.
The method of claim 1 or 2, wherein the absence of said antibody indicates that the animal has not been 1) infected with wild-type BVDV, or 2) immunized with a conventional BVDV vaccine, or has been immunized with a chimeric pestivirus expressing a pronghorn pestivirus Erns protein. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što odsutnost navedenog protutijela ukazuje da životinja nije bila 1) zaražena divljim tipom BVDV, ili 2) imunizirana uobičajenim cjepivom protiv BVDV, ili je imunizirana kimernim virusom kuge koji eksprimira protein Erns virusa kuge vitoroge antilope.
The use of the kit of claim 5, wherein one of said reagents is an antibody that specifically binds to an epitope present in wild-type BVDV or a conventional BVDV vaccine, but which epitope is not present in a pronghorn pestivirus Erns protein. 
Upotreba kompleta u skladu s patentnim zahtjevom 5, naznačena time što je jedan od navedenih reagensa protutijelo koje se specifično veže na epitop prisutan kod divljeg tipa BVDV ili u uobičajenom cjepivu protiv BVDV, no gdje navedeni epitop nije prisutan u proteinu Erns virusa kuge vitoroge antilope.
The herbicidal composition according to Claim 1, wherein the compound (2) is at least one compound selected from the group consisting of a polyoxyalkylene sorbitan fatty acid ester and a polyoxyalkylene fatty acid ester. 
Herbicidni pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je spoj (2) barem jedan spoj odabran iz skupine koju čine polioksialkilen sorbitan ester masnih kiselina i ester polioksialkilen masne kiseline.